相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model
Hiroki Takashima et al.
SCIENTIFIC REPORTS (2017)
Variation in life history traits and transcriptome associated with adaptation to diet shifts in the ladybird Cryptolaemus montrouzieri
Hao-Sen Li et al.
BMC GENOMICS (2016)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Nuclear translocation of heparan sulfate proteoglycans and their functional significance
Ilona Kovalszky et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2014)
Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior
B. J. Grindel et al.
MATRIX BIOLOGY (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
Target deconvolution techniques in modern phenotypic profiling
Jiyoun Lee et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
The Overexpression of Hypomethylated miR-663 Induces Chemotherapy Resistance in Human Breast Cancer Cells by Targeting Heparin Sulfate Proteoglycan 2 (HSPG2)
Haiyan Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
Daniela A. Ferraro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Heparan Sulfate and Heparanase as Modulators of Breast Cancer Progression
Angelica M. Gomes et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis
Arthur A. DeCarlo et al.
BMC BIOTECHNOLOGY (2012)
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Hailing Lu et al.
CLINICAL CANCER RESEARCH (2012)
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Crosstalk between Human IgG Isotypes and Murine Effector Cells
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2012)
Phage displaya powerful technique for immunotherapy 1. Introduction and potential of therapeutic applications
Justyna Bazan et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
Hailing Lu et al.
CLINICAL CANCER RESEARCH (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting
Achilleas D. Theocharis et al.
FEBS JOURNAL (2010)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
N. Turner et al.
ONCOGENE (2010)
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
B. Corkery et al.
ANNALS OF ONCOLOGY (2009)
Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis
Jason J. Zoeller et al.
MATRIX BIOLOGY (2009)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen
Yong Tang et al.
JOURNAL OF IMMUNOLOGY (2007)
Fc gamma R: The key to optimize therapeutic antibodies?
Sophie Siberil et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages
James Melrose et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels
R Wild et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Genes that mediate breast cancer metastasis to lung
AJ Minn et al.
NATURE (2005)
Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma
A Toma et al.
BRITISH JOURNAL OF CANCER (2005)
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells
LD Shultz et al.
JOURNAL OF IMMUNOLOGY (2005)
Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density
R Niwa et al.
CLINICAL CANCER RESEARCH (2005)
Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo
C Savore et al.
CLINICAL & EXPERIMENTAL METASTASIS (2005)
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
J Yang et al.
CELL (2004)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
The biology of human natural killer-cell subsets
MA Cooper et al.
TRENDS IN IMMUNOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
B Elenbaas et al.
GENES & DEVELOPMENT (2001)
分享论文
